Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 5/20 | 0.37 |
| ▸ | MMP9 | P14780 | 4/20 | 0.37 |
| ▸ | MMP7 | P09237 | 2/20 | 0.37 |
| ▸ | MMP3 | P08254 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879572 | 0.87 | TAS2R8 (0.46) | TAS2R8MMP1MMP9TSHRALDH1A1 | |
| SCHEMBL13879511 | 0.87 | ALDH1A1 (0.45) | TAS2R8TSHRALDH1A1 | |
| SCHEMBL13879535 | 0.77 | NOX4 (0.40) | TAS2R8TSHRALDH1A1HSD17B10CCR5 | |
| SCHEMBL13879557 | 0.76 | MMP1 (0.51) | TAS2R8MMP1MMP9MMP3ALDH1A1 | |
| SCHEMBL13879580 | 0.76 | KMT2A (0.46) | TAS2R8MMP1MMP9MMP3HSD17B10 | |
| SCHEMBL11724977 | 0.73 | MEN1 (0.41) | TAS2R8TSHRALDH1A1HSD17B10 | |
| SCHEMBL13879356 | 0.71 | TAS2R8 (0.40) | TAS2R8MMP1MMP9MMP7MMP3 | |
| SCHEMBL12408226 | 0.70 | MMP1 (0.43) | TAS2R8MMP1MMP9MMP7MMP3 | |
| SCHEMBL11612934 | 0.70 | KMT2A (0.58) | TSHRALDH1A1 | |
| SCHEMBL13879412 | 0.68 | TAS2R8 (0.42) | TAS2R8MMP1MMP9MMP7MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | TAS2R8 4662/4885MMP1 349/4885MMP9 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.